Literature DB >> 15939726

Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance.

E Perugini1, C Rapezzi, T Piva, O Leone, L Bacchi-Reggiani, L Riva, F Salvi, L Lovato, A Branzi, R Fattori.   

Abstract

OBJECTIVE: To investigate the prevalence and distribution of gadolinium (Gd) enhancement at cardiac magnetic resonance (CMR) imaging in patients with cardiac amyloidosis (CA) and to look for associations with clinical, morphological, and functional features. PATIENTS AND
DESIGN: 21 patients with definitely diagnosed CA (nine with immunoglobulin light chain amyloidosis and 12 transthyretin related) underwent Gd-CMR.
RESULTS: Gd enhancement was detected in 16 of 21 (76%) patients. Sixty six of 357 (18%) segments were enhanced, more often at the mid ventricular level. Transmural extension of enhancement within each patient significantly correlated with left ventricular (LV) end systolic volume (r = 0.58). The number of enhanced segments correlated with LV end diastolic volume (r = 0.76), end systolic volume (r = 0.6), and left atrial size (r = 0.56). Segments with > 50% extensive transmural enhancement more often were severely hypokinetic or akinetic (p = 0.001). Patients with > 2 enhanced segments had significantly lower 12 lead QRS voltage and Sokolow-Lyon index. No relation was apparent with any other clinical, morphological, functional, or histological characteristics.
CONCLUSION: Gd enhancement is common but not universally present in CA, probably due to expansion of infiltrated interstitium. The segmental and transmural distribution of the enhancement is highly variable, and mid-ventricular regions are more often involved. Enhancement appears to be associated with impaired segmental and global contractility and a larger atrium.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939726      PMCID: PMC1860803          DOI: 10.1136/hrt.2005.061911

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  25 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.

Authors:  Joakim Bergström; Asa Gustavsson; Ulf Hellman; Knut Sletten; Charles L Murphy; Deborah T Weiss; Alan Solomon; Bert-Ove Olofsson; Per Westermark
Journal:  J Pathol       Date:  2005-06       Impact factor: 7.996

3.  Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy.

Authors:  R Fattori; G Rocchi; F Celletti; P Bertaccini; C Rapezzi; G Gavelli
Journal:  Am Heart J       Date:  1998-11       Impact factor: 4.749

Review 4.  The systemic amyloidoses.

Authors:  R H Falk; R L Comenzo; M Skinner
Journal:  N Engl J Med       Date:  1997-09-25       Impact factor: 91.245

Review 5.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

6.  Cardiovascular magnetic resonance in cardiac amyloidosis.

Authors:  Alicia Maria Maceira; Jayshree Joshi; Sanjay Kumar Prasad; James Charles Moon; Enrica Perugini; Idris Harding; Mary Noelle Sheppard; Philip Alexander Poole-Wilson; Philip Nigel Hawkins; Dudley John Pennell
Journal:  Circulation       Date:  2005-01-03       Impact factor: 29.690

7.  MRI evaluation of amyloid myopathy.

Authors:  J P Metzler; J L Fleckenstein; C L White; R G Haller; E P Frenkel; R G Greenlee
Journal:  Skeletal Radiol       Date:  1992       Impact factor: 2.199

8.  Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance.

Authors:  J A McCrohon; J C C Moon; S K Prasad; W J McKenna; C H Lorenz; A J S Coats; D J Pennell
Journal:  Circulation       Date:  2003-06-23       Impact factor: 29.690

9.  Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction.

Authors:  Aernout M Beek; Harald P Kühl; Olga Bondarenko; Jos W R Twisk; Mark B M Hofman; Willem G van Dockum; Cees A Visser; Albert C van Rossum
Journal:  J Am Coll Cardiol       Date:  2003-09-03       Impact factor: 24.094

10.  Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

Authors:  James C C Moon; Bhavesh Sachdev; Andrew G Elkington; William J McKenna; Atul Mehta; Dudley J Pennell; Philip J Leed; Perry M Elliott
Journal:  Eur Heart J       Date:  2003-12       Impact factor: 29.983

View more
  34 in total

1.  Noninvasive diagnosis of cardiac amyloidosis by MRI and echochardiography.

Authors:  Jing Wang; Xiangquan Kong; Haibo Xu; Guofeng Zhou; Dandan Chang; Dingxi Liu; Li Zhang; Mingxing Xie
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

Review 2.  The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy.

Authors:  Mouaz H Al-Mallah; Mohammad Naseem Shareef
Journal:  Heart Fail Rev       Date:  2011-07       Impact factor: 4.214

3.  MRI differentiation of cardiomyopathy showing left ventricular hypertrophy and heart failure: differentiation between cardiac amyloidosis, hypertrophic cardiomyopathy, and hypertensive heart disease.

Authors:  Minako Takeda; Yasuo Amano; Masaki Tachi; Hitomi Tani; Kyoichi Mizuno; Shinichiro Kumita
Journal:  Jpn J Radiol       Date:  2013-08-31       Impact factor: 2.374

4.  An unusual case of cardiac amyloidosis.

Authors:  Chiara Bucciarelli-Ducci; Dudley J Pennell
Journal:  J Gen Intern Med       Date:  2007-09       Impact factor: 5.128

5.  Author reply--an unusual case of cardiac amyloidosis.

Authors:  Brian Garibaldi; David Zaas
Journal:  J Gen Intern Med       Date:  2007-09       Impact factor: 5.128

Review 6.  Transthyretin-related amyloidoses and the heart: a clinical overview.

Authors:  Claudio Rapezzi; Candida Cristina Quarta; Letizia Riva; Simone Longhi; Ilaria Gallelli; Massimiliano Lorenzini; Paolo Ciliberti; Elena Biagini; Fabrizio Salvi; Angelo Branzi
Journal:  Nat Rev Cardiol       Date:  2010-05-18       Impact factor: 32.419

Review 7.  Identifying the etiology: a systematic approach using delayed-enhancement cardiovascular magnetic resonance.

Authors:  Annamalai Senthilkumar; Maulik D Majmudar; Chetan Shenoy; Han W Kim; Raymond J Kim
Journal:  Heart Fail Clin       Date:  2009-07       Impact factor: 3.179

8.  Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis.

Authors:  Ralf Wassmuth; Hassan Abdel-Aty; Steffen Bohl; Jeanette Schulz-Menger
Journal:  Eur Radiol       Date:  2011-03-29       Impact factor: 5.315

9.  The role of echocardiography in the non-invasive diagnosis of cardiac amyloidosis.

Authors:  Federico Cacciapuoti
Journal:  J Echocardiogr       Date:  2015-07-14

Review 10.  Heart transplantation and end-stage cardiac amyloidosis: a review and approach to evaluation and management.

Authors:  Jerry D Estep; Arvind Bhimaraj; A M Cordero-Reyes; Brian Bruckner; Matthias Loebe; Guillermo Torre-Amione
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.